Pepti Review (2026): $99 Semaglutide, One Open Question

Pepti (hellopepti.com) advertises injectable semaglutide at $99 a month, the same $99 at every titration dose, cancellable at any time.¹ That is the lowest semaglutide subscription we have verified anywhere, and if it holds it is a genuinely significant number for anyone whose maintenance dose is 1.0 mg or above, because dose-tiered pricing is where most cheap GLP-1 offers stop being cheap.

We checked it in August 2026. The $99 is what the site renders, what its catalogue object carries, and what its dedicated cost page and three cross-sell surfaces all repeat. It is also sitting on top of something we could not reconcile, and you should read that part before you subscribe.

The rung, as published

$99 a month on subscription, flat across every dose in the titration schedule, with no minimum term — the subscription terms allow cancellation at any time, effective at the end of the current cycle, and a pause of up to 90 days.¹ A single one-time purchase, rather than a subscription, is $124. That 1.25× relationship holds across the catalogue, which is at least internally consistent.

Oral semaglutide is $249 a month, and tirzepatide is $199 injectable or $399 oral. If you are choosing between the routes rather than the sellers, oral versus injectable semaglutide is the argument, not the price list.

The contradiction we could not resolve

Pepti's product pages ship a second price structure that nothing on the site displays. The server payload for its semaglutide page carries a per-dose array — $299 at 0.25 mg, $349 at 0.5 mg, $399 at 1.0 mg, $449 at 2.4 mg — and the equivalent tirzepatide array runs $349 to $549. No client-side code reads either one. They render nowhere. Nothing in the purchasable catalogue references them.

Meanwhile the cost page says, in as many words, that all doses cost one flat monthly price, the same all-in price at every titration dose, $99 a month.

Those two things cannot both describe what you will be charged. We took the rendered $99, because it is what the page shows, what the catalogue carries and what four surfaces repeat — but a per-dose ladder averaging roughly three times the headline, sitting in production data, is not a cosmetic leftover we are comfortable dismissing. We tried to break the tie at the checkout and could not: the checkout endpoint accepts only POST, so there is no way to read a price out of it without walking a real intake and entering payment details.

So we are recording this as unresolved rather than deciding it. If you sign up, the useful thing you can do is check what your card is actually charged at 1.0 mg and at 2.4 mg, not just at the starting dose. And if you are budgeting, do it twice — once at $99 and once at $399 — so you know in advance which answer you can live with. Our cost calculator will run both.

Thirty-six states, or fifty

Pepti's shipping page, its state-availability page, its shipping policy, its providers page and its own homepage title all say 36 states, and the list is published: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Virginia and Washington.¹

Its terms of service say the services are available in 50 states. Four surfaces against one: treat 36 as the operative number, and check your own state on the availability page before you spend an hour on an intake.

When your card is charged

Same pattern, smaller stakes. The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before a licensed provider reviews your intake.² A refund policy is the operative document in a dispute, so assume you are charged first and refunded if you are declined — Pepti states that a provider denial produces a full refund in five to ten business days.

Nothing is refundable once medication ships, and cancelling mid-cycle is not pro-rated.

What else is on the shelf

Pepti carries 68 items — nasal sprays, oral drops, recovery peptides, an anti-aging line, at-home blood panels. Most of that is beside the point for a semaglutide buyer, but three items are worth naming so you can avoid them: retatrutide, melanotan II and IGF-1 LR3. Retatrutide has no FDA approval in any form anywhere; the other two are not approvable consumer products. We would not treat any of them as an option, and a semaglutide shopper has no reason to be in that part of the catalogue at all.

Who prescribes, and who compounds

Pepti names its clinicians properly: Dr. Gene Lee, MD, medical director, board-certified in family medicine and licensed in 26 named states; and Dr. Laeeq Butt, MD MBA, chief medical officer, internal medicine, licensed in 15. Both have full bios with education and board certifications.

Neither publishes an NPI, so neither can be checked against the national registry — an odd gap, given how thorough the rest of the disclosure is. The pharmacy is described only as "independent FDA-registered 503A or 503B compounding pharmacies" and is never named, which matters more than it sounds for a compounded product; the reasoning is in is compounded semaglutide still legal in 2026?. The legal entity is registered at a Delaware address that is a well-known registered-agent office rather than an operating site.

The regulatory screen

We queried the FDA's live warning-letter index for the trading name and the legal entity in August 2026 and got no company-column match for either.³ The neighbourhood is instructive, though: a search for the word "pepti" returns a long list of peptide sellers that do carry enforcement letters. Pepti is not among them, and the pass that established this correctly returned a known February 2026 letter for an unrelated seller used as a control.

Where it lands

If the $99 is what you are charged at your maintenance dose, this is the cheapest verified semaglutide subscription we have seen, and the flat-at-every-dose structure is exactly right for anyone titrating up — see the semaglutide dose ladder for why that structure is worth so much. If the unrendered ladder is what eventually bills, the same subscription is a mid-market product with a very good advertisement.

We cannot tell you which, and neither can the site. Weigh it against The Edit's $209, where every figure reconciled, and against the rest of the programs we track.